Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: A systematic review and cost-effectiveness analysis

Research output: Book/ReportCommissioned report

Original languageEnglish
Publication statusPublished - 2018

Cite this